Shots:

• ProQR to receive $20M up front- $30M as an equity investment & is also eligible to receive ~$1.25B as development- regulatory- and commercialization milestones along with royalties on product sales
• The companies collaborated to develop editing oligonucleotides for five targets by using ProQR’s Axiomer RNA editing platform
• ProQR’s Axiomer platform technology enables the editing of single nucleotides in RNA in targeted & specific manner. The technology is designed to recruit endogenous ADAR enzymes to selected target adenosine in a disease-associated RNA

Ref: Globe Newswire | Image: Eli Lilly